869 related articles for article (PubMed ID: 30865796)
21. Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy.
Ballantyne CM; McKenney JM; MacDougall DE; Margulies JR; Robinson PL; Hanselman JC; Lalwani ND
Am J Cardiol; 2016 Jun; 117(12):1928-33. PubMed ID: 27138185
[TBL] [Abstract][Full Text] [Related]
22. Bempedoic Acid: A New Drug for an Old Problem.
Nguyen D; Du N; Sulaica EM; Wanat MA
Ann Pharmacother; 2021 Feb; 55(2):246-251. PubMed ID: 32674598
[TBL] [Abstract][Full Text] [Related]
23. Bempedoic acid, an inhibitor of ATP citrate lyase for the treatment of hypercholesterolemia: early indications and potential.
Brandts J; Ray KK
Expert Opin Investig Drugs; 2020 Aug; 29(8):763-770. PubMed ID: 32564642
[TBL] [Abstract][Full Text] [Related]
24. Bempedoic acid: effect of ATP-citrate lyase inhibition on low-density lipoprotein cholesterol and other lipids.
Paton DM
Drugs Today (Barc); 2020 Sep; 56(9):573-582. PubMed ID: 33025951
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive review of statin-intolerance and the practical application of Bempedoic Acid.
Yarrarapu SNS; Goyal A; Venkata VS; Panchal V; Sivasubramanian BP; Du DT; Jakulla RS; Pamulapati H; Afaq MA; Owens S; Dalia T
J Cardiol; 2024 Jul; 84(1):22-29. PubMed ID: 38521120
[TBL] [Abstract][Full Text] [Related]
26. Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial.
Rubino J; MacDougall DE; Sterling LR; Hanselman JC; Nicholls SJ
Atherosclerosis; 2021 Mar; 320():122-128. PubMed ID: 33514449
[TBL] [Abstract][Full Text] [Related]
27. Real-world utilization of bempedoic acid in an academic preventive cardiology practice.
Warden BA; Cardiology BA; Purnell JQ; Duell PB; Fazio S
J Clin Lipidol; 2022; 16(1):94-103. PubMed ID: 34924351
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
Robinson JG; Farnier M; Krempf M; Bergeron J; Luc G; Averna M; Stroes ES; Langslet G; Raal FJ; El Shahawy M; Koren MJ; Lepor NE; Lorenzato C; Pordy R; Chaudhari U; Kastelein JJ;
N Engl J Med; 2015 Apr; 372(16):1489-99. PubMed ID: 25773378
[TBL] [Abstract][Full Text] [Related]
29. Evaluating pharmacokinetics of bempedoic acid in the treatment of hypercholesterolemia.
Cicero AFG; Fogacci F; Cincione I
Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1031-1038. PubMed ID: 34197267
[No Abstract] [Full Text] [Related]
30. Adenosine Triphosphate Citrate Lyase and Fatty Acid Synthesis Inhibition: A Narrative Review.
Duarte Lau F; Giugliano RP
JAMA Cardiol; 2023 Sep; 8(9):879-887. PubMed ID: 37585218
[TBL] [Abstract][Full Text] [Related]
31. Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia.
Santos RD; Ruzza A; Hovingh GK; Wiegman A; Mach F; Kurtz CE; Hamer A; Bridges I; Bartuli A; Bergeron J; Szamosi T; Santra S; Stefanutti C; Descamps OS; Greber-Platzer S; Luirink I; Kastelein JJP; Gaudet D;
N Engl J Med; 2020 Oct; 383(14):1317-1327. PubMed ID: 32865373
[TBL] [Abstract][Full Text] [Related]
32. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Sabatine MS; Giugliano RP; Keech AC; Honarpour N; Wiviott SD; Murphy SA; Kuder JF; Wang H; Liu T; Wasserman SM; Sever PS; Pedersen TR;
N Engl J Med; 2017 May; 376(18):1713-1722. PubMed ID: 28304224
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials.
Laufs U; Ballantyne CM; Banach M; Bays H; Catapano AL; Duell PB; Goldberg AC; Gotto AM; Leiter LA; Ray KK; Bloedon LT; MacDougall D; Zhang Y; Mancini GBJ
J Clin Lipidol; 2022; 16(3):286-297. PubMed ID: 35346603
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis.
Wang X; Zhang Y; Tan H; Wang P; Zha X; Chong W; Zhou L; Fang F
Cardiovasc Diabetol; 2020 Aug; 19(1):128. PubMed ID: 32787939
[TBL] [Abstract][Full Text] [Related]
35. Factors Associated With Enhanced Low-Density Lipoprotein Cholesterol Lowering With Bempedoic Acid.
Ballantyne CM; Bays HE; Louie MJ; Smart J; Zhang Y; Ray KK
J Am Heart Assoc; 2022 Aug; 11(15):e024531. PubMed ID: 35916348
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of bempedoic acid alone or combining with other lipid-lowering therapies in hypercholesterolemic patients: a meta-analysis of randomized controlled trials.
Zhao X; Ma X; Luo X; Shi Z; Deng Z; Jin Y; Xiao Z; Tan L; Liu P; Jiang S; Shu Y; Tang B; Qiu C
BMC Pharmacol Toxicol; 2020 Dec; 21(1):86. PubMed ID: 33276805
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of bempedoic acid in patients with and without metabolic syndrome: Pooled analysis of data from four phase 3 clinical trials.
Shapiro MD; Taub PR; Louie MJ; Lei L; Ballantyne CM
Atherosclerosis; 2023 Aug; 378():117182. PubMed ID: 37517922
[TBL] [Abstract][Full Text] [Related]
38. Effect of Bempedoic Acid on atherogenic lipids and inflammation: A meta-analysis.
Masson W; Lobo M; Lavalle-Cobo A; Molinero G
Clin Investig Arterioscler; 2021; 33(3):117-126. PubMed ID: 33328138
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus.
Gutierrez MJ; Rosenberg NL; Macdougall DE; Hanselman JC; Margulies JR; Strange P; Milad MA; McBride SJ; Newton RS
Arterioscler Thromb Vasc Biol; 2014 Mar; 34(3):676-83. PubMed ID: 24385236
[TBL] [Abstract][Full Text] [Related]
40. Bempedoic acid lowers high-sensitivity C-reactive protein and low-density lipoprotein cholesterol: Analysis of pooled data from four phase 3 clinical trials.
Stroes ESG; Bays HE; Banach M; Catapano AL; Duell PB; Laufs U; Mancini GBJ; Ray KK; Sasiela WJ; Zhang Y; Gotto AM
Atherosclerosis; 2023 May; 373():1-9. PubMed ID: 37075696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
